These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34656072)

  • 1. Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial.
    van Doorn L; Heersche N; de Man FM; de Bruijn P; Bijl I; Oomen-de Hoop E; Eskens FALM; van der Gaast A; Mathijssen RHJ; Bins S
    Clin Pharmacol Ther; 2022 Feb; 111(2):455-460. PubMed ID: 34656072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of the Acidic Beverage Cola on the Absorption of Erlotinib in Patients With Non-Small-Cell Lung Cancer.
    van Leeuwen RW; Peric R; Hussaarts KG; Kienhuis E; IJzerman NS; de Bruijn P; van der Leest C; Codrington H; Kloover JS; van der Holt B; Aerts JG; van Gelder T; Mathijssen RH
    J Clin Oncol; 2016 Apr; 34(12):1309-14. PubMed ID: 26858332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, and 5-fluorouracil.
    Sekido M; Fujita KI; Kubota Y; Ishida H; Takahashi T; Ohkuma R; Tsunoda T; Ishikawa F; Shibanuma M; Sasaki Y
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1127-1135. PubMed ID: 30972456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib: A Randomized Crossover Pharmacokinetic Study.
    de Man FM; Hussaarts KGAM; de With M; Oomen-de Hoop E; de Bruijn P; van Halteren HK; van der Burg-de Graauw NCHP; Eskens FALM; van Gelder T; van Leeuwen RWF; Mathijssen RHJ
    Clin Pharmacol Ther; 2019 Jun; 105(6):1456-1461. PubMed ID: 30570132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of esomeprazole on the bioavailability of afatinib: A pharmacokinetic cross-over study in patients with non-small cell lung cancer.
    Veerman GDM; Hurkmans DP; Paats MS; Oomen-de Hoop E; van der Leest CH; van Thiel ERE; Aerts JGJV; van Leeuwen RW; Dingemans AC; Mathijssen RHJ
    Biomed Pharmacother; 2022 Nov; 155():113695. PubMed ID: 36126454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
    Choi Y; Han H; Shin D; Lim KS; Yu KS
    Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations.
    Walravens J; Brouwers J; Spriet I; Tack J; Annaert P; Augustijns P
    Clin Pharmacokinet; 2011 Nov; 50(11):725-34. PubMed ID: 21973269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors.
    Tan AR; Gibbon DG; Stein MN; Lindquist D; Edenfield JW; Martin JC; Gregory C; Suttle AB; Tada H; Botbyl J; Stephenson JJ
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1635-43. PubMed ID: 23636448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
    Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
    Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of esomeprazole with/without acetylsalicylic acid, omeprazole and lansoprazole on pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Andersson T; Nagy P; Niazi M; Nylander S; Galbraith H; Ranjan S; Wallentin L
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):217-27. PubMed ID: 24677117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.
    Jacobs BA; Meulenaar J; Rosing H; Pluim D; Tibben MM; de Vries N; Nuijen B; Huitema AD; Beijnen JH; Schellens JH; Marchetti S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1201-7. PubMed ID: 27103124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of drug-drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer.
    Lau YY; Gu W; Lin T; Viraswami-Appanna K; Cai C; Scott JW; Shi M
    Cancer Chemother Pharmacol; 2017 Jun; 79(6):1119-1128. PubMed ID: 28424965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of dose and type of proton pump inhibitor use on risk of fractures and osteoporosis treatment in older Australian women: A prospective cohort study.
    van der Hoorn MMC; Tett SE; de Vries OJ; Dobson AJ; Peeters GMEEG
    Bone; 2015 Dec; 81():675-682. PubMed ID: 26319499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.
    Kaur Mukker J; Dukes G; Wang L; Huh S; Khudyakov P; Nishihara M; Chen C
    Clin Transl Sci; 2022 May; 15(5):1281-1290. PubMed ID: 35218604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial.
    Sung JJ; Barkun A; Kuipers EJ; Mössner J; Jensen DM; Stuart R; Lau JY; Ahlbom H; Kilhamn J; Lind T;
    Ann Intern Med; 2009 Apr; 150(7):455-64. PubMed ID: 19221370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and relative bioavailability of a fixed-dose combination of enteric-coated naproxen and non-enteric-coated esomeprazole magnesium.
    Wang-Smith L; Fort J; Zhang Y; Sostek M
    J Clin Pharmacol; 2012 May; 52(5):670-80. PubMed ID: 21628602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of esomeprazole, a proton pump inhibitor on the pharmacokinetics of sonidegib in healthy volunteers.
    Zhou J; Quinlan M; Glenn K; Boss H; Picard F; Castro H; Sellami D
    Br J Clin Pharmacol; 2016 Oct; 82(4):1022-9. PubMed ID: 27277189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
    Veerman GDM; Hussaarts KGAM; Peric R; Oomen-de Hoop E; Landa KD; van der Leest CH; Broerse SD; Rutten HB; Belderbos HNA; Steendam CMJ; Paats MS; Koolen SLW; Dingemans AC; van Gelder T; van Leeuwen RWF; Aerts JGJV; Mathijssen RHJ
    Clin Pharmacokinet; 2021 Jan; 60(1):69-77. PubMed ID: 32557346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Pharmacokinetics/Pharmacodynamics of Fixed-Dose Combination of Esomeprazole and Calcium Carbonate (AD-206) to the Conventional Esomeprazole.
    Bae S; Kwon J; Lee SB; Jang IJ; Yu KS; Lee S
    Drug Des Devel Ther; 2021; 15():5099-5108. PubMed ID: 34992346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.